ArticleMedicine2025
The accelerating effect of sugar on wound healing delayed by bevacizumab: A case report.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleBevacizumab, a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor is associated with delayed wound healing. Sugar, a traditional remedy for wound healing, has shown significant efficacy in accelerating recovery. Here, we developed a new strategy for managing bevacizumab-associated delayed wound healing with the topical application of sugar. PATIENT CONCERNS: A 42-year-old female with non-small cell lung cancer and brain metastases who underwent emergency surgical treatment for acute appendicitis while on bevacizumab developed delayed wound healing postoperatively. DIAGNOSES: At 50 days postoperatively, the wound was still approximately 2 cm, indicating bevacizumab-associated delayed wound healing.
interventionsThe patient had enlarged brain metastases and increased edema due to discontinuation of bevacizumab. Bevacizumab was reintroduced without complete wound healing. Concurrently, topical sugar was applied following routine wound disinfection. OUTCOMES: The wound completely healed 21 days after initiating sugar therapy, coinciding with ongoing bevacizumab treatment. LESSONS: The patient's wound healed completely with the application of topical sugar, even in the context of ongoing bevacizumab therapy, highlighting the efficacy of sugar in managing bevacizumab-induced delayed wound healing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.